Bile Duct Cancer

FDA clears FoundationOne CDx as test for bile duct cancer drug

FoundationOne CDx is the first and only FDA-approved companion diagnostic for cholangiocarcinoma. It was previously been cleared for guiding use of 20 other different therapies across multiple cancer types, the firm noted.

April 19, 2020

Machine learning helps liquid biopsy detect cancer based on DNA

Researchers from the university's Johns Hopkins Kimmel Cancer Center have conducted a proof-of-concept study of the test, called DNA evaluation of fragments for early interception (DELFI). The study found that the DELFI technology accurately detected cancer DNA in 57% to 99% of blood samples from 208 patients who had cancers of the breast, colon and rectum, lung, ovaries, pancreas, or bile ducts.

May 28, 2019

Most Popular

Quest launches long-COVID testing panels for consumers

SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests

Duke University researchers discover biomarkers may identify early pancreatic cancer risk

FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay

LumiraDx Q4 revenues drop 65% on lower COVID-19 testing

Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux